Global Next Generation Antibody Therapeutics Market Insights and Forecast to 2028

Market Analysis and Insights: Global Next Generation Antibody Therapeutics Market

Due to the COVID-19 pandemic and Spain-Ukraine War Influence, the global market for Next Generation Antibody Therapeutics estimated at US$ 12257.15 million in the year 2022, is projected to reach a revised size of US$ 39442.45 million by 2028, growing at a CAGR of 21.51% during the forecast period 2022-2028.

The USA market for Next Generation Antibody Therapeutics is estimated to increase from US$ 7362.24 million in 2022 to reach US$ 20256.78 million by 2028, at a CAGR of 18.38% during the forecast period of 2022-2028.

The Europe market for Next Generation Antibody Therapeutics is estimated to increase from US$ 2284.07 million in 2022 to reach US$ 9019.50 million by 2028, at a CAGR of 25.72% during the forecast period of 2022 through 2028.

The Japan market for Next Generation Antibody Therapeutics is estimated to increase from US$ 1154.2 million in 2022 to reach US$ 3337.61 million by 2028, at a CAGR of 19.36% during the forecast period of forecast years.

The global key companies of Next Generation Antibody Therapeutics include Roche, Amgen, Takeda, Pfizer, Seagen Inc., ADC Therapeutics SA, Astellas, Daiichi Sankyo, and Immunomedics (Gilead), etc. In 2021, the global top five players had a share approximately 88.78% in terms of revenue.

Report Includes

This report presents an overview of global market for Next Generation Antibody Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.

This report researches the key producers of Next Generation Antibody Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Next Generation Antibody Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, Japan, China, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Next Generation Antibody Therapeutics revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Next Generation Antibody Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Next Generation Antibody Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Roche, Amgen, Takeda, Pfizer, Seagen Inc., ADC Therapeutics SA, Astellas, Daiichi Sankyo, and Immunomedics (Gilead), etc.

By Company

Roche

Amgen

Pfizer

Takeda

Daiichi Sankyo

Seagen

Astellas

Immunomedics

GSK

Immunocore

ADC Therapeutics

Segment by Type

Antibody Drug Conjugate (ADC)

Bispecific Antibody (BsAb)

Segment by Application

Cancer

Haemophilia

Other Non-Cancer Diseases

By Region

North America

United States

Canada

Mexico

Asia-Pacific

China

Japan

South Korea

India

Southeast Asia

Rest of Asia

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Middle East

Africa

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Next Generation Antibody Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Next Generation Antibody Therapeutics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America by Type, by Application and by country, revenue for each segment.

Chapter 7: Europe by Type, by Application and by country, revenue for each segment.

Chapter 8: Asia Pacific by Type, by Application and by region, revenue for each segment.

Chapter 9: South America by Type, by Application and by country, revenue for each segment.

Chapter 10: Middle East and Africa by Type, by Application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Next Generation Antibody Therapeuticsrevenue, gross margin, and recent development, etc.

Chapter 12: Analyst's Viewpoints/Conclusions